GILEAD SCIENCES INC.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000CKGBP2
GILD
GILEAD SCIENCES INC.
GICS: -
·
Sektor: -
·
Sub-Sektor: -
NAME
GILEAD SCIENCES INC.
ISIN
US3755581036
TICKER
GILD
MIC
XNAS
REUTERS
GILD.OQ
BLOOMBERG
GILD US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 22.10.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, Calif. More than 40 abstracts will be presented with key data, including 11 abstracts reporting new data on primary biliary cholan...
Gilead Sciences
Sa., 19.10.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 ca...
Gilead Sciences
Mi., 09.10.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business up...
Gilead Sciences
Mi., 09.10.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presenta...
Gilead Sciences
Mo., 07.10.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of ci...
Gilead Sciences
Mi., 02.10.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income ...
Gilead Sciences
Do., 12.09.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were 2 incident cases a...
Gilead Sciences
Di., 10.09.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910912771...
Gilead Sciences
Do., 05.09.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presenta...
Gilead Sciences
Mi., 21.08.2024
Gilead Sciences
US3755581036
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Wells Fargo Healthcare Conference on Wednesday, September 4 at 11:00 AM Eastern Time
Morgan Stanley Annual Global Healthcare Conference on Thursday, September 5 at 12:20 PM Eastern Time
Baird Global Healthcare...
Gilead Sciences
Informationen zu Product Placements
